Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$116.80 USD
-0.93 (-0.79%)
Updated Nov 6, 2024 04:02 PM ET
After-Market: $116.78 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$116.80 USD
-0.93 (-0.79%)
Updated Nov 6, 2024 04:02 PM ET
After-Market: $116.78 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Cerner (CERN) Misses on Q3 Earnings, Bookings Decline Y/Y
by Zacks Equity Research
Despite a tepid third quarter, Cerner's (CERN) bookings guidance for the fourth quarter is encouraging.
Varian Medical (VAR) Misses on Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Year-over-year decline in Varian Medical's (VAR) proton therapy segment is the primary cause behind the company's lackluster fourth-quarter performance.
GNC Holdings (GNC) Lags Q3 Earnings & Revenues, Margins Down
by Zacks Equity Research
GNC Holdings (GNC) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from the recent hurricanes and lower sales at the U.S. & Canada and manufacturing/wholesale segments.
Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.
Boston Scientific's (BSX) Q3 Earnings In Line, Guidance Up
by Zacks Equity Research
Despite back-to-back natural disasters, Boston Scientific managed to register strong year-over-year increase in both earnings and revenues in the third quarter on balanced growth across all segments.
McKesson (MCK) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
McKesson (MCK) reported strong second-quarter numbers owing to stable performance from Distribution Solutions business.
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
Thermo Fisher (TMO) Q3 Earnings & Sales Top, Guidance Up
by Zacks Equity Research
On solid third-quarter performance, a favorable foreign exchange environment and the recently closed acquisition of Patheon, Thermo Fisher (TMO) has raised its full-year 2017 guidance.
LabCorp (LH) Beats Q3 Earnings Estimates, Raises Guidance
by Zacks Equity Research
Banking on strong third-quarter show and considering a gradually improving foreign exchange scenario, LabCorp (LH) increased its earlier provided 2017 outlook.
Walgreens Boots (WBA) Tops Q4 Earnings, Issues 2018 View
by Zacks Equity Research
Walgreens Boots (WBA) surpasses the Zacks Consensus Estimate for both the counts in Q4 on continued prescription growth and strength in the Retail Pharmacy USA division.
Baxter (BAX) Beats on Earnings & Sales in Q3, 2017 View Up
by Zacks Equity Research
Baxter (BAX) exited the third quarter on a solid note, courtesy of stellar performances by the company's hospital products and renal segments.
NuVasive (NUVA) Q3 Earnings Top, Revenues Lag, Guidance Cut
by Zacks Equity Research
NuVasive's robust top-line growth in Q3 was driven by strong international performance. However, U.S. sales declined on procedural volume challenges and an adverse impact of the recent natural disasters.
Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) rides high on its product and service segments in Q1.
Illumina (ILMN) Tops Q3 Earnings & Revenues, Raises Guidance
by Zacks Equity Research
Illumina (ILMN) rides high on sequencing consumables and instruments as well as microarray portfolios in Q3 earnings.
Abaxis (ABAX) Posts In-Line Earnings in Q2, Lags Revenues
by Zacks Equity Research
Abaxis (ABAX) misses the Zacks Consensus Estimate for revenues due to softness in the medical market in Q2. Weak margins are a concern as well.
Edwards Lifesciences (EW) Q3 Earnings, Sales Lag, View Intact
by Zacks Equity Research
Edwards Lifesciences (EW) misses the Zacks Consensus Estimate on both the counts in Q3 due to adverse impact from recent natural disasters in the Caribbean and the United States.
Anthem's (ANTM) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) strong third-quarter results were driven by solid enrollment growth.
PetMed (PETS) Tops Q2 Earnings & Sales Estimates, Margins Up
by Zacks Equity Research
The year-over-year rise in earnings of PetMed (PETS) was driven by an increase in sales and improved margins.
Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View
by Zacks Equity Research
Centene's (CNC) strong third-quarter earnings were driven by solid revenue growth.
Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
We are upbeat about Varian Medical's oncology business that accounted for around 95% of the company's total revenue in fourth-quarter 2017.
Baxter International (BAX) Q3 Earnings: What's in Store?
by Zacks Equity Research
Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.
Quest Diagnostics (DGX) Beats Earnings in Q3, Updates View
by Zacks Equity Research
Despite hurricanes related financial impact, Quest Diagnostics (DGX) posted year-over-year growth in Q3 on recent acquisitions, tie-ups and strength in several advanced diagnostic offerings.
Company News For Oct 19, 2017
by Zacks Equity Research
Companies in the News are: FOGO,ABT,AGN,EA
Varian Medical (VAR) Initiates Halcyon Treatment in Europe
by Zacks Equity Research
Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.
Abbott (ABT) Exceeds Q3 Earnings, '17 Guidance Narrowed
by Zacks Equity Research
Abbott (ABT) posted promising Q3 results primarily on the back of strong EPD sales and emerging market expansion.